A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Completed · Phase 3 · Has a placebo group

Conditions studied: Psoriatic Arthritis

In brief

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR) subjects with active Psoriatic Arthritis (PsA).

Key facts

Study ID

NCT03896581

Run by

UCB Biopharma SRL

People needed

400

Starts

2019-03-28

Expected to finish

2022-02-14

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is male or female at least 18 years of age
• Female subjects must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception
• Documented diagnosis of adult-onset Psoriatic Arthritis (PsA) meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 6 months prior to Screening with active PsA and must have at Baseline tender joint count (TJC) >=3 out of 68 and swollen joint count (SJC) >=3 out of 66
• Subject must be negative for rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies
• Subject must have at least 1 active psoriatic lesion(s) and/or a documented history of psoriasis (PSO)
• Subject has a history of inadequate response (lack of efficacy after at least 3 months of therapy at an approved dose) or intolerance to treatment with 1 or 2 tumor necrosis factor alpha (TNF(α)) inhibitors for either PsA or PSO
• Subjects currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics (including mild opioids), corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

You may not qualify if…

• Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study
• Subjects with current or prior exposure to any biologics except tumor necrosis factor (TNF) inhibitors for the treatment of PsA or PSO
• Subject has an active infection or a history of recent serious infections
• Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
• Subject has a diagnosis of inflammatory conditions other than PSO or PsA. Subjects with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease at Screening or Baseline
• Subject had acute anterior uveitis within 6 weeks of Baseline
• Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
• Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and guttate PSO, or drug-induced PSO)
• Presence of active suicidal ideation, or moderately severe major depression or severe major depression
• Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

Where it is running

• Pa0011 50035 — San Diego, California, United States
• Pa0011 50004 — Tustin, California, United States
• Pa0011 50033 — Palm Harbor, Florida, United States
• Pa0011 50037 — Tampa, Florida, United States
• Pa0011 50039 — Atlanta, Georgia, United States
• Pa0011 50024 — Boise, Idaho, United States
• Pa0011 50028 — Lexington, Kentucky, United States
• Pa0011 50023 — Baton Rouge, Louisiana, United States
• Pa0011 50015 — Hagerstown, Maryland, United States
• Pa0011 50026 — Wheaton, Maryland, United States
• Pa0011 50047 — Boston, Massachusetts, United States
• Pa0011 50019 — Lansing, Michigan, United States
• Pa0011 50016 — St Louis, Missouri, United States
• Pa0011 50005 — Freehold, New Jersey, United States
• Pa0011 50029 — Albuquerque, New Mexico, United States
• Pa0011 50010 — Brooklyn, New York, United States
• Pa0011 50011 — New York, New York, United States
• Pa0011 50034 — Rochester, New York, United States
• Pa0011 50125 — Charlotte, North Carolina, United States
• Pa0011 50031 — Salisbury, North Carolina, United States
• Pa0011 50040 — Vandalia, Ohio, United States
• Pa0011 50020 — Duncansville, Pennsylvania, United States
• Pa0011 50064 — Philadelphia, Pennsylvania, United States
• Pa0011 50006 — Wyomissing, Pennsylvania, United States
• Pa0011 50017 — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.